Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been assigned an average recommendation of “Moderate Buy” from the twenty-four ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have given a hold rating and eighteen have given a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $298.09.

Several brokerages have recently weighed in on ALNY. JPMorgan Chase & Co. raised their price target on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a report on Monday, August 26th. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th.

Alnylam Pharmaceuticals Trading Down 0.8 %

Shares of NASDAQ ALNY opened at $253.91 on Wednesday. The stock has a market cap of $32.75 billion, a P/E ratio of -96.91 and a beta of 0.32. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The firm has a 50-day moving average of $268.29 and a 200 day moving average of $247.45.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same quarter in the prior year, the company posted $1.15 earnings per share. The firm’s quarterly revenue was down 33.3% on a year-over-year basis. As a group, sell-side analysts expect that Alnylam Pharmaceuticals will post -2.21 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 5,219 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now directly owns 78,880 shares in the company, valued at $19,797,302.40. This represents a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the sale, the executive vice president now owns 13,191 shares in the company, valued at $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,370 shares of company stock valued at $2,100,703. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ALNY. American Trust purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $309,000. Tidal Investments LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 75.1% in the third quarter. Tidal Investments LLC now owns 20,544 shares of the biopharmaceutical company’s stock worth $5,650,000 after buying an additional 8,811 shares in the last quarter. Sanctuary Advisors LLC boosted its position in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Sanctuary Advisors LLC now owns 4,558 shares of the biopharmaceutical company’s stock worth $1,254,000 after acquiring an additional 2,181 shares during the last quarter. Teachers Retirement System of The State of Kentucky boosted its position in shares of Alnylam Pharmaceuticals by 4.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 34,713 shares of the biopharmaceutical company’s stock worth $9,547,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Toronto Dominion Bank grew its stake in Alnylam Pharmaceuticals by 27.3% during the third quarter. Toronto Dominion Bank now owns 15,466 shares of the biopharmaceutical company’s stock valued at $4,254,000 after acquiring an additional 3,315 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.